H.C. Wainwright initiated coverage on OmniAb with a new price target
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
H.C. Wainwright initiated coverage of OmniAb with a rating of Buy and set a new price target of $11.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2023 | $6.00 | Outperform | RBC Capital Mkts |
| 4/21/2023 | $8.00 | Buy | The Benchmark Company |
| 4/13/2023 | $10.00 | Buy | Craig Hallum |
| 2/22/2023 | $10.00 | Outperform | Cowen |
| 2/13/2023 | $11.00 | Buy | H.C. Wainwright |
RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00
The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00
Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00
Agreement is focused on OmnidAb™ single domain technology OmniAb to receive revenue for discovery services as well as potential equity and royalties OmniAb, Inc. (NASDAQ:OABI) and ArrowMark Partners ("ArrowMark") today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors ("Viking"). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential equity and royalties for the discovery of novel antibodies for targets defined by Mabtrx. "
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates. "Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering our partnered pipeline and creating potential sources of enduring value within our portfolio. Importantly, OmniAb's innovative technology platform and operational model
OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in three investor conferences during the month of November. 2025 Truist Securities BioPharma Symposium, November 6 at the Lotte New York Palace Hotel. Matt Foehr, Chief Executive Officer, will participate in one-on-one meetings with investors on Thursday, November 6th. Stifel 2025 Healthcare Conference, November 11-13 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Wednesday, November 12th. Jefferies Global Healthcare Conference – London, November 17-20 at the Waldorf Hilton. Matt Foehr, Chief Executive Officer, wi
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
10-Q - OmniAb, Inc. (0001846253) (Filer)
8-K - OmniAb, Inc. (0001846253) (Filer)
EFFECT - OmniAb, Inc. (0001846253) (Filer)
OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates. "Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering our partnered pipeline and creating potential sources of enduring value within our portfolio. Importantly, OmniAb's innovative technology platform and operational model
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and nine months ended September 30, 2025, after the close of the U.S. financial markets on Tuesday, November 4, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter 2025 financial results and business updates Date: Tuesday, November 4, 2025 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549 8228
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. "Our business is performing very well as we continued our momentum in partner additions in the second quarter, reaching 100 active partners. This is a testament to the strength of our innovative technology platform and to our team's execution, and puts us on pace for one of our strongest years ever in partner adds. Additionally, a recent further streamlining of our operations enhances the scalability and long-term value of our business," said Matt Foehr, Chief E
SC 13G/A - OmniAb, Inc. (0001846253) (Subject)
SC 13D/A - OmniAb, Inc. (0001846253) (Subject)